Programmable cancer treatments: Engineering biology approaches for living cures.

Living cures are cell-based, programmable therapies that integrate the latest learnings in immunology and synthetic biology. Although Adoptive Cell Therapies (ACTs) have transformed the treatment landscape of haematological malignancies by harnessing the powerful anti-tumour properties of immune cells, commercialisation and ensuring access is challenging. Their application in solid tumour treatment has been hindered by the immunosuppressive tumour microenvironment (TME) and its associated physical barriers. Conversely, bacterial immunotherapies offer cost-effective solutions by utilising tumour-colonising bacteria that trigger localised inflammatory responses within the TME. The authors briefly examine advancements in ACT and propose bacterial immunotherapies as an alternative or complementary treatment modality with potential use either as standalone therapies or in conjunction with other treatments.